1. Home
  2. AGIO vs FORTY Comparison

AGIO vs FORTY Comparison

Compare AGIO & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$30.98

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Formula Systems (1985) Ltd.

FORTY

Formula Systems (1985) Ltd.

N/A

Current Price

$127.28

Market Cap

1.8B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
AGIO
FORTY
Founded
2007
1985
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2013
1998

Fundamental Metrics

Financial Performance
Metric
AGIO
FORTY
Price
$30.98
$127.28
Analyst Decision
Buy
Analyst Count
10
0
Target Price
★ $46.11
N/A
AVG Volume (30 Days)
★ 1.2M
702.0
Earning Date
11-05-2026
11-23-2026
Dividend Yield
N/A
★ 9.69%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $43,011,000.00
N/A
Revenue This Year
$227.92
N/A
Revenue Next Year
$96.10
N/A
P/E Ratio
★ N/A
$36.65
Revenue Growth
N/A
N/A
52 Week Low
$22.24
$102.01
52 Week High
$46.00
$190.56

Technical Indicators

Market Signals
Indicator
AGIO
FORTY
Relative Strength Index (RSI) 44.24 57.37
Support Level $26.41 $105.71
Resistance Level $35.77 $132.18
Average True Range (ATR) 1.85 3.27
MACD -0.54 0.16
Stochastic Oscillator 30.47 86.67

Price Performance

Historical Comparison
AGIO
FORTY

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.

Share on Social Networks: